Navigation Links
Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts
Date:8/19/2008

Frost & Sullivan and Strategic Directions International Magazine Identify

Waters Mass Spectrometers as Technology Leaders

MILFORD, Mass., Aug. 19 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) today announced that Waters(R) SYNAPT(TM) High Definition MS(TM) (HDMS(TM)) System was recognized by Frost & Sullivan for a Product Innovation of the Year award, and Strategic Directions International's Instrument Business Outlook (IBO) selected the Xevo(TM) TQ MS System as the Best New Product at the 2008 American Society of Mass Spectrometry (ASMS) annual meeting.

"We are appreciative of the due diligence from both Frost & Sullivan and IBO, and are honored by their respective recognition in evaluating Waters SYNAPT HDMS and Xevo TQ MS," said Brian W. Smith, Vice President, Mass Spectrometry Operations, for the Waters Division. "Waters mass spectrometry is experiencing significant momentum in the marketplace. Our scientists have developed novel innovations and the beneficiaries have been our customers who are realizing new levels of success in reaching their own goals and achievements."

In 2006, Waters introduced the SYNAPT HDMS System, the first mass spectrometry (MS) system to leverage high-efficiency ion mobility-based measurements and to advance research in proteomics, structural biology and small molecule experiments. "This unique combination of technologies allow scientists to differentiate samples by their size, shape, and charge, as well as mass, which has enabled the separation, detection, and characterization of components not possible with conventional mass spectrometry," said Frost & Sullivan Research Analyst, Lakshman Koundinya.

The Xevo TQ MS System, an advanced tandem quadrupole mass
'/>"/>

SOURCE Waters Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
2. Waters Offers U.S. Water Authorities Complimentary Drinking Water Testing for the Presence of Pharmaceuticals
3. Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008
4. Vanderbilt University Medical Center and Waters Collaborate on Tissue Imaging Research Using SYNAPT HDMS
5. 2007: A Watershed Year for Lupus Research and Education
6. Extracts of catfish caught in polluted waters cause breast cancer cells to multiply
7. Waters Corporation Receives Market Leadership and Product Innovation Awards
8. Out of the woods: Physicians get urban disaster training in forests, gorges and waters
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Medical Blogs May Threaten Patient Privacy 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5Health News:Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance 2Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 2Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 3Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 4Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 2Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 3Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 4Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 5Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 6
Breaking Medicine Technology:China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Vivakor Announces New Acquisition Strategy 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3New artificial enzyme safer for nature 10482 1New artificial enzyme safer for nature 10482 2Now hear this 10478 1